Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Teva's second phase III study of SD-809 in TD shows statistically significant results A phase III clinical trial, AIM-TD, evaluating Teva Pharmaceutical Industries' SD-809 (deutetrabenazine) to treat tardive dyskinesia (TD) demonstrated a statistically valid treatment benefit. Contract Research & Services > Clinical Trials > News
Ligand Pharmaceuticals licensing deals with Seelos Therapeutics for four programs Ligand Pharmaceuticals has licensed rights to four programs to Seelos Therapeutics a newly formed biopharmaceutical firm focused on central nervous system (CNS), respiratory and other disorders.
Contract Research & Services > Contract Services > News Evotec forms research collaboration with Inserm Transfert in oncology Evotec has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm).
Contract Research & Services > Contract Research > News Sanaria's preventative vaccine for malaria gets FDA fast track designation The US Food and Drug Administration (FDA) has granted Fast Track designation for Sanaria's preventative vaccine for malaria, Sanaria PfSPZ Vaccine.
Regulatory Affairs > News
UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharmaceuticals’ Strensiq (asfotase alfa) drug to treat rare inherited bone disorder in children.
Drug Research > Drug Delivery > News Teva's second phase III study of SD-809 in TD shows statistically significant results By PBR Staff Writer
A phase III clinical trial, AIM-TD, evaluating Teva Pharmaceutical Industries' SD-809 (deutetrabenazine) to treat tardive dyskinesia (TD) demonstrated a statistically valid treatment benefit.
Contract Research & Services > Clinical Trials > News FDA approves Janssen’s new type 2 diabetes combination therapy By PBR Staff Writer
Janssen Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for a fixed-dose combination therapy to treat adults with type 2 diabetes.
Regulatory Affairs > News

Latest News and Insight by Sector

Production & Manufacturing

GSK names Emma Walmsley as new CEO
GlaxoSmithKline (GSK) has named Emma Walmsley as its new chief executive officer (CEO).
Production & Manufacturing > Manufacturing > News
Sanofi files patent infringement suit against Merck
By PBR Staff Writer
French pharmaceutical firm Sanofi has filed a lawsuit against Merck’s international unit over alleged patent infringements.
Production & Manufacturing > Manufacturing > News

Drug Research

UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq
By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharmaceuticals’ Strensiq (asfotase alfa) drug to treat rare inherited bone disorder in children.
Drug Research > Drug Delivery > News
Turing advances several experimental compounds into pre-clinical development
Turing Pharmaceuticals has advanced several experimental compounds into pre-clinical development.
Drug Research > Drug Discovery & Development > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Ligand Pharmaceuticals licensing deals with Seelos Therapeutics for four programs
Ligand Pharmaceuticals has licensed rights to four programs to Seelos Therapeutics a newly formed biopharmaceutical firm focused on central nervous system (CNS), respiratory and other disorders.
Contract Research & Services > Contract Services > News
Evotec forms research collaboration with Inserm Transfert in oncology
Evotec has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm).
Contract Research & Services > Contract Research > News

Automation

AstraZeneca selects LLamasoft as supply chain design technology partner
AstraZeneca has selected LLamasoft’s Supply Chain Guru and Data Guru as tools of choice for supply chain modelling.
Automation > IT & Software > News
Ligand Pharmaceuticals signs OmniAb license deal with TeneoBio
Ligand Pharmaceuticals has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio.
Automation > IT & Software > News

Regulatory Affairs

Sanaria's preventative vaccine for malaria gets FDA fast track designation
The US Food and Drug Administration (FDA) has granted Fast Track designation for Sanaria's preventative vaccine for malaria, Sanaria PfSPZ Vaccine.
Regulatory Affairs > News
FDA approves Janssen’s new type 2 diabetes combination therapy
By PBR Staff Writer
Janssen Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for a fixed-dose combination therapy to treat adults with type 2 diabetes.
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery